Cargando…

TOSO interacts with SYK and enhances BCR pathway activation in chronic lymphocytic leukemia

BACKGROUND: TOSO, also named Fas inhibitory molecule 3 (FAIM3), has recently been identified as an immunoglobulin M (IgM) Fc receptor (FcμR). Previous studies have shown that TOSO is specifically over-expressed in chronic lymphocytic leukemia (CLL). However, the functions of TOSO in CLL remain unkno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yan-Ru, Yu, Zhen, Xiong, Wen-Jie, Liu, Xu-Xiang, Liu, Hui-Min, Cui, Rui, Wang, Qi, Chen, Wen-Ming, Qiu, Lu-Gui, Yi, Shu-Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478576/ https://www.ncbi.nlm.nih.gov/pubmed/32784334 http://dx.doi.org/10.1097/CM9.0000000000000999

Ejemplares similares

Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells
por: Purroy, Noelia, et al.
Publicado: (2016)

Modulation of BCR Signaling by the Induced Dimerization of Receptor-Associated SYK
por: Westbroek, Mark L., et al.
Publicado: (2017)

Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia
por: Li, Heng, et al.
Publicado: (2017)

Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma
por: Sonowal, Himangshu, et al.
Publicado: (2023)

BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia
por: Smith, Lindsay D., et al.
Publicado: (2019)

Immunoglobulin replacement therapy targeting the BCR in chronic lymphocytic leukemia
por: Ferrer, Gerardo
Publicado: (2018)

Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation
por: Romero-Camarero, Isabel, et al.
Publicado: (2013)

Syk Tyrosine Kinase and B Cell Antigen Receptor (BCR) Immunoglobulin-α Subunit Determine BCR-mediated Major Histocompatibility Complex Class II–restricted Antigen Presentation
por: Lankar, Danielle, et al.
Publicado: (1998)

P1267: HSP110 FAVORS BCR SIGNALING THROUGH SYK PHOSPHORYLATION IN DIFFUSE LARGE B CELL LYMPHOMA
por: Cabaud Gibouin, V., et al.
Publicado: (2022)

Phosphoinositide 3′-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia
por: Hoellenriegel, Julia, et al.
Publicado: (2011)

BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo
por: Schleiss, Cédric, et al.
Publicado: (2019)

SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia
por: Paiva, Cody, et al.
Publicado: (2017)

BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia
por: Falchi, Lorenzo, et al.
Publicado: (2016)

SYK-targeted dendritic cell-mediated cytotoxic T lymphocytes enhance the effect of immunotherapy on retinoblastoma
por: Chen, Xuemei, et al.
Publicado: (2018)

FcγRIIb-BCR coligation inhibits B-cell receptor signaling in chronic lymphocytic leukemia
por: Bosch, Rosa, et al.
Publicado: (2020)

Activation of the Syk tyrosine kinase is insufficient for downstream signal transduction in B lymphocytes
por: Hsueh, Robert C, et al.
Publicado: (2002)

SYK expression level distinguishes control from BRCA1-mutated lymphocytes
por: Zahavi, Tamar, et al.
Publicado: (2018)

Dectin-1/Syk signaling triggers neuroinflammation after ischemic stroke in mice
por: Ye, Xin-Chun, et al.
Publicado: (2020)

Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL
por: Wang, Tao, et al.
Publicado: (2019)

SYK Allelic Loss and the Role of Syk-Regulated Genes in Breast Cancer Survival
por: Blancato, Jan, et al.
Publicado: (2014)

miR-25-3p promotes endothelial cell angiogenesis in aging mice via TULA-2/SYK/VEGFR-2 downregulation
por: Lian, Chong, et al.
Publicado: (2020)

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor
por: Burke, Russell T, et al.
Publicado: (2014)

Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment
por: Guo, Ailin, et al.
Publicado: (2017)

IGF-IR determines the fates of BCR/ABL leukemia
por: Xie, Jingjing, et al.
Publicado: (2015)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
por: Kim, Jaeseung C., et al.
Publicado: (2023)

Prognostic biomarker SYK and its correlation with immune infiltrates in glioma
por: Wang, Changxin, et al.
Publicado: (2023)

SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia
por: Uckun, Fatih M., et al.
Publicado: (2014)

Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia
por: Boros, Katalin, et al.
Publicado: (2015)

SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism
por: Polak, Anna, et al.
Publicado: (2020)

Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition
por: Brattås, Marte Karen, et al.
Publicado: (2022)

Prognostic value and outcome for acute lymphocytic leukemia in children with MLL rearrangement: a case-control study
por: Qiu, Kun-yin, et al.
Publicado: (2022)

Syk inhibitors in clinical development for hematological malignancies
por: Liu, Delong, et al.
Publicado: (2017)

Protocol for isolation and analysis of the leukemia stem cells in BCR-ABL-driven chronic myelogenous leukemia mice
por: Liu, Chang, et al.
Publicado: (2023)

TLR4 signals in B lymphocytes are transduced via the B cell antigen receptor and SYK
por: Schweighoffer, Edina, et al.
Publicado: (2017)

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)

Get Syk and get cycling
por: Williams, Ruth
Publicado: (2006)

Syk and Yea Shall Find
por: Wolozin, Benjamin, et al.
Publicado: (2015)

Higher‐order interactions of Bcr‐Abl can broaden chronic myeloid leukemia (CML) drug repertoire
por: Liu, Yonglan, et al.
Publicado: (2023)

Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia
por: Sun, Xiaoyan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8449no225snf3dctj6ogupo0h1